INSIGHT SPONSOR
We are grateful for the financial support of our sponsor Agilent Technologies. As always, Nature carries sole responsibility for all editorial content and peer review.
Top of pageSponsor: Agilent Technologies
Agilent Technologies is the leader in commercial lab-on-a-chip products. With more than 70 applications and 3500 scientific citations, the Agilent 2100 bioanalyzer is the world's most successful microfluidics-based platform.
This issue of Nature Insight highlights the huge potential of microfluidics based lab-on-a-chip technology. The articles span the bridge from the goal of downsizing analytical instrumentation by integration of more features on microfluidics chips, to applications in the area of medical diagnostics.
Agilent's 2100 bioanalyzer reflects this potential of microfluidics-based lab-on-a-chip technology, with its breadth of assays and applications:
- RNA assays, featuring RIN (RNA Integrity Number) - a novel way to standardized RNA quality control for microarray and RT-PCR experiments.
- Protein assays, featuring protein and antibody size - concentration and purity determination supported by the 2100 bioanalyzer software for compliance with 21 CFR Part 11.
- DNA assays, featuring routine DNA sizing - concentration determination for a variety of applications such as GMO detection, food speciation, gene expression analysis, PCR product and restriction digest analysis.
- Cell assays, featuring protein expression monitoring, transfection efficiency monitoring, apoptosis detection and gene silencing in cell culture.
Agilent is pleased to be supporting this Insight about lab-on-a-chip technology. For more information about the Agilent 2100 bioanalyzer instrument please visit: www.agilent.com/chem/70-reasons
